PCSK9 and coronary artery disorder: A 52-year-old woman with a history of coronary artery disease (CAD), atrial and ventricular arrhythmia, type 1 diabetes mellitus, hypertension, and elevated lipoprotein(a) (Lp(a)) was initiated on Repatha 140 mg every two weeks for lipid optimization. Although not formally approved for Lp(a) reduction, PCSK9 inhibitors remain the only FDA-approved drugs shown to lower Lp(a) [9].